Transient elastography and fibrosis-4 index as predictors of hepatocellular carcinoma in hepatitis C virus patients with sustained virological response

Table 1 Baseline demographic and clinical characteristics of the included hepatitis C virus sustained virological response patients (n = 425), mean ± SD/n (%)

Variables
Age, years	61 ± 10.2
Female sex	277 (65.2)
White non-Hispanic	240 (56.5)
Type 2 diabetes mellitus	156 (36.7)
BMI, kg/m2	27.98 ± 5.24
AST, U/L, median IQR	70 (45-108)
ALT, U/L, median IQR	86 (54-135)
Albumin, g/dL, median IQR	3.8 (3.5-4.1)
Total bilirubin, mg/dL, median IQR	0.7 (0.5-1)
INR, median IQR	1.1 (1-1.2)
Alpha-fetoprotein, ng/mL, median IQR	8.2 (4.7-15)
Pre-T F3	137 (32.2)
Pre-T F4	265 (67.8)
CSPH	85 (20)
Previous decompensation	15 (3.5)
LSM, kPa, median IQR	15 (11.8-23.2)
FIB-4 index, median IQR	2.94 (1.89-4.85)
Platelets, × 109/L	165 ± 71
Time of follow-up, months	48 ± 23
HCC	26 (6)
Time until HCC since EOT, months
≥ 12	9 (34.6)
≥ 24	17 (65.4)

IQR: Interquartile range; Pre-T: Pre-treatment; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio; CSPH: Clinically significant portal hypertension; LSM: Liver stiffness measure; FIB-4: Fibrosis-4; EOT: End of treatment; HCC: Hepatocellular carcinoma.